In vitro evaluation of tigecycline and comparative agents in 3049 clinical isolates: 2001 to 2002
Authors:
- Samuel K. BouchillonSBSamuel K. Bouchillon
- Daryl J. HobanDHDaryl J. Hoban
- Brian M. JohnsonBJBrian M. Johnson
- Tim M. StevensTSTim M. Stevens
- Michael J. DowzickyMDMichael J. Dowzicky
- David H. WuDWDavid H. Wu
- Patricia A. BradfordPBPatricia A. Bradford
- 1 April 2005
- journal article
- research article
- Published by Elsevier in Diagnostic Microbiology and Infectious Disease
- Vol. 51 (4) , 291-295
Abstract
No abstract availableKeywords
This publication has 9 references indexed in Scilit:
- Novel antibacterial agents for the treatment of serious Gram-positive infectionsExpert Opinion on Investigational Drugs, 2003
- Efflux-Mediated Resistance to Tigecycline (GAR-936) in Pseudomonas aeruginosa PAO1Antimicrobial Agents and Chemotherapy, 2003
- In Vitro and In Vivo Activities of Tigecycline (GAR-936), Daptomycin, and Comparative Antimicrobial Agents against Glycopeptide-IntermediateStaphylococcus aureusand Other Resistant Gram-Positive PathogensAntimicrobial Agents and Chemotherapy, 2002
- Antibiotic resistance among clinical isolates of Acinetobacter in the UK, and in vitro evaluation of tigecycline (GAR-936)Journal of Antimicrobial Chemotherapy, 2002
- In vitro antimicrobial activity of GAR-936 tested against antibiotic-resistant gram-positive blood stream infection isolates and strains producing extended-spectrum β-lactamasesDiagnostic Microbiology and Infectious Disease, 2001
- Mutations in the Interdomain Loop Region of the tetA (A) Tetracycline Resistance Gene Increase Efflux of Minocycline and GlycylcyclinesMicrobial Drug Resistance, 2000
- Preclinical Pharmacology of GAR‐936, a Novel Glycylcycline Antibacterial AgentPharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, 2000
- Antimicrobial activity and spectrum of the new glycylcycline, GAR-936 tested against 1,203 recent clinical bacterial isolatesDiagnostic Microbiology and Infectious Disease, 2000
- In Vitro and In Vivo Antibacterial Activities of a Novel Glycylcycline, the 9- t -Butylglycylamido Derivative of Minocycline (GAR-936)Antimicrobial Agents and Chemotherapy, 1999